08.00 · Coffee and Registration
08.30 · Chairman's Opening Remarks
Dr. Lei Guo
Division of Systems Toxicology
National Center for Toxicological Research (NCTR)
Food and Drug Administration (FDA)
08.45 · Prediction of Toxicity Potential using In Vitro Screening Assays from the EPA’s ToxCast Program
Dr. Keith Houck
Toxicologist
National Center for Computational Toxicology
U.S. Environmental Protection Agency
09.30 · High Throughput Screening for In Vitro Toxicity Testing for Genotoxicity and Carcinogenicity
Dr. Willem Schoonen
Group Leader, Department of Pharmacology
Schering-Plough
10.15 · Networking Coffee Break
10.45 · Evaluation of a Battery of Early Genotoxicity Assays to Predict Regulatory Testing
Dr. Franck Atienzar
Head In Vitro Toxicology Unit
UCB-Pharma
11.30 · Evaluating Drug Induced Liver Toxicity Using Cellular Systems Cytotoxicity Assays
Dr. Lei Guo
Division of Systems Toxicology
National Center for Toxicological Research (NCTR)
Food and Drug Administration (FDA)
12.15 · Networking Lunch
14.00 · Cell-Based, High-Content Analysis in Drug Discovery and Development for Predictive Screening, Elucidating Mechanisms, and Monitoring Target Organ toxicity
Dr. Peter O'Brien (formerly of Pfizer)
Veterinary Clinical Pathologist
University College Dublin
14.45 · Development of a Multiparameter Screening Assay for Neurotoxicity Assessment
Dr. David Hayes
Director R&D
Millipore Corporation
15.30 · Networking Coffee Break
16.00 · In Vitro Data for Skin Sensitization:
Modelling and Assay Development
Dr. Cameron MacKay
Project Leader - Toxicology Modelling
Unilever - Safety & Environmental Assurance Centre
16.45 · Predicting Chronic Toxicity Based on the Decoding of Mitochondrial Behavior
Dr. Nathalie Compagnone
CEO
Innovative Concepts in Drug Development(ICDD)
17.30 · Open Discussion and Chair's Closing Comments
18.00 · End of Day One
08.00 · Coffee and Registration
08.30 · Chairman's Opening Remarks
Dr. Albert P. Li
President and CEO
In Vitro ADMET Laboratories LLC
Advanced Pharmaceutical Sciences Inc
08.45 · Outcome of PredTox, a public-private European Collaboration (FP6)
Dr. Laura Suter-Dick
Section Head Investigative Toxicology
F. Hoffmann-La Roche
09.30 · Engineering Microscale Rodent and Human Liver Models for Drug Development
Dr. Salman Khetani
Research Affiliate
Massachusetts Institute of Technology
10.15 · Networking Coffee Break
10.45 · The Role of ADME in Facilitating Drug Discovery and Development; Where are we, and Where do we Need to Go?
Dr. Robert J. Guttendorf
Vice President, Pharmacology and Experimental Therapeutics
Sequoia Pharmaceuticals, Inc.
11.30 · The Role of Metabolic Profiling in Biomedical Sciences
Dr. Muireann Coen
Research Fellow, Biomolecular Medicine
Imperial College, London
12.15 · Networking Lunch
14.00 · In vitro Evaluation of the Role of Xenobiotic Metabolism in Drug Toxicity
Dr. Albert P. Li
President and CEO
In Vitro ADMET Laboratories LLC
Advanced Pharmaceutical Sciences Inc
14.45 · Reducing the Cost of Drug Development using ADME Studies:
Recent FDA Guidelines and Case Studies
Dr. Katya Tsaioun
CEO
Apredica
15.30 · Networking Coffee Break
16.00 · Predicting the Extent of CYP Induction In Vivo from In Vitro Data: Implications for Exposure to Parent Compound and it's Metabolites
Dr. Lisa Almond
Principal Scientist
Simcyp Limited
16.45 · TRANSIL High Protein Binding Assay: A Novel Method for Sticky
Lipophilic Compounds Circumventing the Analytical Challenges of Strong Plasma Protein Binders
Dr. Hinnerk Boriss
CEO
Sovicell GmbH
17.30 · · Open Discussion and Chair's Closing Comments
18.00 · Close Conference